Tracer library / [177Lu]Lu-DOTA-NI-FAPI-04

Structure of DOTA-NI-FAPI-04 (unlabelled parent compound, from PubChem) — Unlabelled parent compoundPubChem CID 172677085

[177Lu]Lu-DOTA-NI-FAPI-04

Also written as [Lu-177]Lu-DOTA-NI-FAPI-04

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 0

Preclinical only, no clinical indication yet Fibroblast activation / tumour stroma Tumour hypoxia

What it is

Compound class: Bivalent FAP-targeting agent containing a hypoxia-sensitive 2-nitroimidazole (NI) moiety conjugated to DOTA-FAPI-04
Target / mechanism: Fibroblast activation protein (FAP), with additional hypoxia-sensitive nitroimidazole moiety PMID 39710979
Clinical application: Solid tumors with hypoxic microenvironment; tumor theranostics PMID 39710979
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-NI-FAPI-04, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.